risks of glp 1 medications The risk in patients taking GLP-1 drugs for obesity or diabetes is higher than with other diabetes drugs, new studies suggest Glucagon-like Receptor-1 agonists for obesity:

Lactobacillus reuteri normalizes altered fear memory in male Cntnap4 knockout mice

W.TaoC.SeoM

Endogenous ZnT-1 has been shown to have a substantial protective effect against I/R injury, which is mediated by the C-terminal domain of the protein through the activation of Ras-ERK signaling

GLP-1s are shaping how people eat, drink, shop, and exercise, and brands need to be paying close attention to these trends. Also referencing the KFF survey, Shil Kothari, president at Gateway Health Alliances Inc., Fairfield, Calif., explains that the awareness of GLP-1s mean that beverage manufacturers must play a proactive role in offering solutions that support those using these medications

Its main symptoms are fatigue, runny nose, headache, nausea and diarrhea